US Institute of Medicine proposes biomarker validation framework
This article was originally published in RAJ Devices
The US Food and Drug Administration should adopt a three-step framework for evaluating and validating biomarkers and convene expert panels to scrutinise those biomarkers that have “regulatory impact”, a US Institute of Medicine (IoM) committee says1.
You may also be interested in...
Unless reauthorized by Congress, the rare pediatric disease program will begin to expire in September; renewal could bring bigger changes across the three PRV programs, including an FDA-requested clarification of biologic products eligible for vouchers and reforms suggested by sponsors and other stakeholders in a recent GAO report.
The SARS-CoV-2 outbreak has the federal government working not only on a vaccine candidate specifically targeted at the novel coronavirus but also thinking more broadly about ways to head off future potential pandemics with emerging pathogens.
US FDA will survey health care providers’ current understanding of analgesic abuse-deterrent formulations and conduct an experimental study exploring the effectiveness of different terminology and descriptions for such products; agency has heard complaints from its own AdComms about terminology around abuse deterrence.